ArticleF1000Research2015
Machine learning models identify molecules active against the Ebola virus
Article in F1000Research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.
- A Systematic Review of Computational Drug Discovery, Development, and Repurposing for Ebola Virus Disease Treatment.Molecules (Basel, Switzerland) · 2017Pooled it
- Article
- Machine Learning and Molecular Modeling for Drug Repurposing Targeting Potential PI3Kα Inhibitors in Post-CoViD-19 Pulmonary Fibrosis.ACS omega · 2026Article
- Drug-induced phospholipidosis as an artifact in antiviral drug repurposing.bioRxiv : the preprint server for biology · 2025Article
- Repurposing lapatinib as a triple antagonist of chemokine receptors 3, 4, and 5.Molecular pharmacology · 2025Article
- Exploring the druggability of the UEV domain of human TSG101 in search for broad-spectrum antivirals.Protein science : a publication of the Protein Society · 2025Article
- High-Throughput Phenotypic Screening and Machine Learning Methods Enabled the Selection of Broad-Spectrum Low-Toxicity Antitrypanosomatidic Agents.Journal of medicinal chemistry · 2023Article
- 1-Sulfonyl-3-amino-1ACS omega · 2023Article
- Learning from COVID-19: How drug hunters can prepare for the next pandemic.Drug discovery today · 2023Article
- Transporter Inhibition Profile for the Antivirals Tilorone, Quinacrine and Pyronaridine.ACS omega · 2023Article
- Artificial Intelligence, Machine Learning, and Big Data for Ebola Virus Drug Discovery.Pharmaceuticals (Basel, Switzerland) · 2023Article
- A Review of the Machine Learning Algorithms for Covid-19 Case Analysis.IEEE transactions on artificial intelligence · 2023Article
- The Commoditization of AI for Molecule Design.Artificial intelligence in the life sciences · 2022Article
- Multiple approaches to repurposing drugs for neuroblastoma.Bioorganic & medicinal chemistry · 2022Article
- Evaluating the performance of drug-repurposing technologies.Drug discovery today · 2022Review
- Robotics and artificial intelligence in healthcare during COVID-19 pandemic: A systematic review.Robotics and autonomous systems · 2021Review
- Defending Antiviral Cationic Amphiphilic Drugs That May Cause Drug-Induced Phospholipidosis.Journal of chemical information and modeling · 2021Article
- Machine Learning Models Identify Inhibitors of SARS-CoV-2.Journal of chemical information and modeling · 2021Article
- Development of Machine Learning Models and the Discovery of a New Antiviral Compound against Yellow Fever Virus.Journal of chemical information and modeling · 2021Article
- A multi-conformational virtual screening approach based on machine learning targeting PI3Kγ.Molecular diversity · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The search for small molecule inhibitors of Ebola virus (EBOV) has led to several high throughput screens over the past 3 years. These have identified a range of FDA-approved active pharmaceutical ingredients (APIs) with anti-EBOV activity
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.